Cargando…
A retrospective survival analysis of Glioblastoma patients treated with selective serotonin reuptake inhibitors
Glioblastoma (GBM) is the most common and aggressive form of malignant glioma in adults with a median overall survival (OS) time of 16–18 months and a median age of diagnosis at 64 years old. Recent work has suggested that depression and psychosocial distress are associated with worse outcomes in pa...
Autores principales: | Otto-Meyer, Sebastian, DeFaccio, Rian, Dussold, Corey, Ladomersky, Erik, Zhai, Lijie, Lauing, Kristen L., Bollu, Lakshmi R., Amidei, Christina, Lukas, Rimas V., Scholtens, Denise M., Wainwright, Derek A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7079579/ https://www.ncbi.nlm.nih.gov/pubmed/32190845 http://dx.doi.org/10.1016/j.bbih.2019.100025 |
Ejemplares similares
-
The Coincidence Between Increasing Age, Immunosuppression, and the Incidence of Patients With Glioblastoma
por: Ladomersky, Erik, et al.
Publicado: (2019) -
Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma
por: Zhai, Lijie, et al.
Publicado: (2021) -
Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies
por: Zhai, Lijie, et al.
Publicado: (2020) -
Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin–Norepinephrine Reuptake Inhibitors
por: Compagner, Chad, et al.
Publicado: (2021) -
Identification
and Characterization of a Novel Indoleamine
2,3-Dioxygenase 1 Protein Degrader for Glioblastoma
por: Bollu, Lakshmi R., et al.
Publicado: (2022)